Overview

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

Status:
Completed
Trial end date:
2017-09-25
Target enrollment:
Participant gender:
Summary
First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Kartos Therapeutics, Inc.